<DOC>
	<DOCNO>NCT01266317</DOCNO>
	<brief_summary>This open-label Phase I/II trial ass feasibility safety combine plasma exchange ( PEX ) , rituximab , conventional corticosteroid administration outcome hospitalize patient acute IPF exacerbation . The specific aim study : 1 . To assess feasibility safety combine PEX , rituximab , conventional corticosteroid administration treatment hospitalize patient acute IPF exacerbation monitor index respiratory ( PaO2 ) cardiovascular function treatment interval . 2 . To assess efficacy combine PEX , rituximab , conventional corticosteroid administration treatment hospitalize patient acute IPF exacerbation patient survival comparison historical control . Patient survival investigation define use composite outcome 60 day survival and/or survival lung transplantation . Subjects 18 80 year age confirm diagnosis IPF , meet study requirement enrol study . A total 10 subject gender ethnic background acute IPF exacerbation hospitalize UPMC enrol study .</brief_summary>
	<brief_title>Combined PEX , Rituximab Steroids Acute IPF Exacerbations</brief_title>
	<detailed_description>This prospective , open-label Phase II , non-randomized clinical trial ass feasibility safety combine plasma exchange ( PEX ) , rituximab , conventional corticosteroid administration patient acute IPF exacerbation . INCLUSION CRITERIA : 1 . A diagnosis idiopathic pulmonary fibrosis fulfills American Thoracic Society Consensus Criteria . 2 . Unexplained worsen development dyspnea hypoxemia within 30 day lead current hospitalization . 3 . Radiographic image show ground-glass abnormality and/or consolidation superimpose background reticular honeycomb pattern consistent UIP . 4 . Intent part treat physician use high dose steroid therapy therapeutic effort treat diagnosis acute IPF exacerbation . EXCLUSION CRITERIA 1 . Diagnosis document infection base upon clinical evaluation microbial testing . 2 . Diagnosis thromboembolic disease clinical assessment . 3 . Diagnosis additional etiology ALI/ARDS base upon clinical assessment include sepsis , aspiration , trauma , inhalational injury , acute pancreatitis , drug toxicity , blood product transfusion reaction , stem cell transplantation . 4 . Diagnosis congestive heart failure account hypoxemia . 5 . Presence active hepatitis B infection . 6 . Coagulopathy define INR &gt; 1.8 , PTT &gt; 2 x control , platelet count &lt; 50K . 7 . Hyperosmolar state diabetic ketoacidosis suggest uncontrolled diabetes mellitus uncontrolled hypertension ( systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg ) would contraindicate use corticosteroid . 8 . Hemodynamic instability define vasopressor requirement would contraindicate use plasmapheresis . 9 . History reaction blood product , murine-derived product , prior exposure human-murine chimeric antibody , 10 . History malignancy . 11 . Inability unwillingness accept blood transfusion . 12 . Inability unwillingness complete post- treatment surveillance 60 day . 13 . Diagnosis major comorbidities expect interfere subject study participation 60 day .</detailed_description>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>A diagnosis idiopathic pulmonary fibrosis fulfills American Thoracic Society Consensus Criteria . Unexplained worsen development dyspnea hypoxemia within 30 day lead current hospitalization . Radiographic image show groundglass abnormality and/or consolidation superimpose background reticular honeycomb pattern consistent UIP . Intent part treat physician use high dose steroid therapy therapeutic effort treat diagnosis acute IPF exacerbation . Diagnosis document infection base upon clinical evaluation microbial testing . Diagnosis thromboembolic disease clinical assessment . Diagnosis additional etiology ALI/ARDS base upon clinical assessment include sepsis , aspiration , trauma , inhalational injury , acute pancreatitis , drug toxicity , blood product transfusion reaction , stem cell transplantation . Diagnosis congestive heart failure account hypoxemia . Presence active hepatitis B infection . Coagulopathy define INR &gt; 1.8 , PTT &gt; 2 x control , platelet count &lt; 50K . Hyperosmolar state diabetic ketoacidosis suggest uncontrolled diabetes mellitus uncontrolled hypertension ( systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg ) would contraindicate use corticosteroid . Hemodynamic instability define vasopressor requirement would contraindicate use plasmapheresis . History reaction blood product , murinederived product , prior exposure humanmurine chimeric antibody , History malignancy . Inability unwillingness accept blood transfusion . Inability unwillingness complete post treatment surveillance 60 day . Diagnosis major comorbidities expect interfere subject study participation 60 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>